This HTML5 document contains 148 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-dehttp://de.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-eshttp://es.dbpedia.org/resource/
n23https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n21http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
n15http://www.grid.ac/institutes/
n24http://
dbpedia-fahttp://fa.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbpedia-frhttp://fr.dbpedia.org/resource/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Lutetium_(177Lu)_oxodotreotide
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:BIOTECanada
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:Advanced_Accelerator_Applications
rdf:type
yago:Group100031264 yago:SocialGroup107950920 wikidata:Q24229398 schema:Organization dbo:Band yago:YagoPermanentlyLocatedEntity yago:YagoLegalActor yago:YagoLegalActorGeo wikidata:Q4830453 wikidata:Q43229 n21:SocialPerson n21:Agent yago:Institution108053576 dbo:Company dbo:Agent owl:Thing yago:Abstraction100002137 yago:WikicatPharmaceuticalCompanies yago:Organization108008335 yago:Company108058098 dbo:Organisation yago:DrugCompany108002578
rdfs:label
Advanced Accelerator Applications Advanced Accelerator Applications Advanced Accelerator Applications Advanced Accelerator Applications
rdfs:comment
Advanced Accelerator Applications, kurz AAA, ist ein pharmazeutisches Unternehmen, spezialisiert auf dem Gebiet der Nuklearmedizin. Die Gruppe agiert in allen drei Segmenten der molekularen Nuklearmedizin (PET, SPECT und Therapie) zur Diagnose und Behandlung schwerer Erkrankungen in den Bereichen Onkologie (Krebs), Neurologie, Kardiologie, Infektionskrankheiten und entzündlichen Erkrankungen. Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) est un groupe pharmaceutique spécialisé en médecine nucléaire moléculaire. L’activité du groupe est axée sur les 3 segments de la médecine nucléaire moléculaire (la TEP/PET, la TEMP/SPECT et la thérapie) pour le diagnostic et le traitement de maladies oncologiques (cancer), neurologiques, cardiologiques, infectieuses et inflammatoires. Advanced Accelerator Applications (AAA), (NASDAQ: AAAP) es un grupo farmacéutico especializado en el campo de la Medicina Nuclear. El grupo opera en los tres segmentos principales de la Medicina Nuclear (PET, SPECT y Terapia) para el diagnóstico y tratamiento de patologías graves en los campos de oncología (cáncer), neurología, cardiología y enfermedades infecciosas e inflamatorias. Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
rdfs:seeAlso
dbr:Peptide_receptor_radionuclide_therapy
foaf:name
Advanced Accelerator Applications
foaf:homepage
n24:www.adacap.com
dbp:name
Advanced Accelerator Applications
dbo:location
dbr:Saint-Genis-Pouilly dbr:France
dcterms:subject
dbc:French_companies_established_in_2002 dbc:Companies_based_in_Auvergne-Rhône-Alpes dbc:Pharmaceutical_companies_established_in_2002 dbc:Pharmaceutical_companies_of_France
dbo:wikiPageID
42427396
dbo:wikiPageRevisionID
1105561227
dbo:wikiPageWikiLink
dbc:French_companies_established_in_2002 dbr:Pancreatic_cancer dbr:Glutamate_carboxypeptidase_II dbr:CERN dbr:Foregut dbr:Radionuclide dbr:Pharmaceutical dbr:Pharmaceutical_industry dbr:Single-photon_emission_computed_tomography dbr:Lutetium dbr:Bombesin dbr:Octreotide dbr:Chemotherapy dbr:Diagnostic_imaging dbr:Radionuclide_therapy dbc:Companies_based_in_Auvergne-Rhône-Alpes dbr:Pancreas dbr:Lutetium_(177lu)_vipivotide_tetraxetan dbr:Gastrointestinal_cancer dbr:Stefano_Buono dbr:Reuters dbr:Diseases dbr:Food_and_Drug_Administration dbr:Radioisotope dbr:Molecular_Imaging dbr:Progression-free_survival dbr:Pancreatic dbc:Pharmaceutical_companies_established_in_2002 dbr:Hindgut dbr:DOTA-TATE dbr:Midgut dbr:GEP-NET dbr:Nuclear_medicine dbr:Therapy dbr:Intestines dbr:Neuroendocrine_tumor dbr:Apoptosis dbr:Rectum dbr:Clinical_trial dbr:France dbr:Chelation dbr:Sidonie_Golombowski-Daffner dbr:Tyrosine dbc:Pharmaceutical_companies_of_France dbr:PET_radiotracer dbr:Breakthrough_therapy dbr:SPECT dbr:Positron_emission_tomography dbr:Cardiology dbr:Saint-Genis-Pouilly dbr:Large_intestine dbr:Gastrointestinal_stromal_tumors dbr:Neurology dbr:Neuroendocrine_tumors dbr:Stomach dbr:Oncology dbr:Neuroendocrine dbr:Acetic_acid_(medical_use) dbr:Somatostatin dbr:Novartis
owl:sameAs
yago-res:Advanced_Accelerator_Applications dbpedia-es:Advanced_Accelerator_Applications dbpedia-fr:Advanced_Accelerator_Applications wikidata:Q16824303 dbpedia-de:Advanced_Accelerator_Applications n23:ehq8 freebase:m.01084ps5 dbpedia-fa:ای‌ای‌ای_کورپوریشن
dbp:wikiPageUsesTemplate
dbt:See_also dbt:Official_website dbt:Infobox_company dbt:Reflist dbt:Start_date dbt:URL
dbp:industry
dbr:Pharmaceutical_industry
dbp:keyPeople
Sidonie Golombowski-Daffner, Chairperson and President
dbp:location
Saint-Genis-Pouilly, France
dbp:numEmployees
>1000
dbp:parent
dbr:Novartis
dbp:products
Gluscan, Dopaview, Fluorochol/Aaacholine, Netspot, Somakit Toc
dbo:abstract
Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) est un groupe pharmaceutique spécialisé en médecine nucléaire moléculaire. L’activité du groupe est axée sur les 3 segments de la médecine nucléaire moléculaire (la TEP/PET, la TEMP/SPECT et la thérapie) pour le diagnostic et le traitement de maladies oncologiques (cancer), neurologiques, cardiologiques, infectieuses et inflammatoires. La médecine nucléaire moléculaire est une spécialité médicale qui utilise des quantités infimes de substances radioactives appelées radiopharmaceutiques pour le diagnostic et le traitement de maladies. En imagerie médicale nucléaire, les traceurs radiopharmaceutiques sont détectés à l’aide de caméras TEP ou TEMP connectées à des ordinateurs pour produire des images précises de la zone observée. La médecine nucléaire peut permettre le traitement de certains types de cancers et autres maladies. L'imagerie moléculaire permet aux médecins de voir le corps fonctionner et d’évaluer ses processus chimiques et biologiques. Les procédures de médecine nucléaire peuvent souvent identifier des anomalies à des stades précoces dans l'évolution d'une maladie – bien avant la mise en évidence de problèmes médicaux par d’autres tests diagnostiques. Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. In late October 2017, Reuters announced that Novartis would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium. On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A. Advanced Accelerator Applications, kurz AAA, ist ein pharmazeutisches Unternehmen, spezialisiert auf dem Gebiet der Nuklearmedizin. Die Gruppe agiert in allen drei Segmenten der molekularen Nuklearmedizin (PET, SPECT und Therapie) zur Diagnose und Behandlung schwerer Erkrankungen in den Bereichen Onkologie (Krebs), Neurologie, Kardiologie, Infektionskrankheiten und entzündlichen Erkrankungen. Advanced Accelerator Applications (AAA), (NASDAQ: AAAP) es un grupo farmacéutico especializado en el campo de la Medicina Nuclear. El grupo opera en los tres segmentos principales de la Medicina Nuclear (PET, SPECT y Terapia) para el diagnóstico y tratamiento de patologías graves en los campos de oncología (cáncer), neurología, cardiología y enfermedades infecciosas e inflamatorias.
gold:hypernym
dbr:Group
skos:closeMatch
n15:grid.476136.1
prov:wasDerivedFrom
wikipedia-en:Advanced_Accelerator_Applications?oldid=1105561227&ns=0
dbo:wikiPageLength
17553
dbo:foundingYear
2002-01-01
dbo:numberOfEmployees
1000
dbo:industry
dbr:Pharmaceutical_industry
dbo:keyPerson
dbr:Sidonie_Golombowski-Daffner
dbo:parentCompany
dbr:Novartis
foaf:isPrimaryTopicOf
wikipedia-en:Advanced_Accelerator_Applications
Subject Item
dbr:Novartis
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:AAA
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
dbo:wikiPageDisambiguates
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:AAAP
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:Advanced_Accelerator_Applications_(AAA)
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
dbo:wikiPageRedirects
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:Stefano_Buono
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
dbo:knownFor
dbr:Advanced_Accelerator_Applications
Subject Item
dbr:Right-to-try_law
dbo:wikiPageWikiLink
dbr:Advanced_Accelerator_Applications
Subject Item
wikipedia-en:Advanced_Accelerator_Applications
foaf:primaryTopic
dbr:Advanced_Accelerator_Applications